April 22, 2024

K-Biotech Innovation Day with BioRN Life Science Cluster

K-Biotech Innovation Day with BioRN Life Science Cluster

Connecting Korean Biotech Innovation with the BioRN Life Science Ecosystem

BioRN Life Science Cluster and 123 Factory GmbH are pleased to invite you to the K-Biotech Innovation Day, an exclusive networking and partnering event bringing together innovative Korean biotech companies and members of the BioRN life science ecosystem.

On 17 September 2026, a delegation of five South Korean biotech and medtech startups will visit Heidelberg to explore potential collaboration opportunities with regional stakeholders. The companies will present their technologies, discuss potential partnership opportunities, and engage with representatives from academia, healthcare institutions, biotech companies, and industry.

The participating companies are actively seeking collaboration partners, clinical and research collaborators, distribution partners, licensing opportunities, and strategic business connections in Europe.

Date: 17 September 2026,14:30 – 18:00
Location:
Business Development Center (bdc) Carl-Friedrich-Gauß-Ring 5, 69124 Heidelberg
Target Audience: Biotech and Pharma Companies, Clinical Researchers, Academic Scientists, Healthcare Institutions, Investors, and Innovation Stakeholders

Meet the Delegating Startups

  1. AAVATAR Therapeutics | AI-Driven AAV Capsid Engineering Platform
    2. AIT Studio | AI-Based Digital Gait Analysis
    3. BICHEDAM | Oral Natural-Product Therapeutics
    4. BeyondDx | AI-Powered Multi-Omics Early Diagnostics
    5. LMNTIC Biotech | Micro-Magnetophoretic CTC Liquid Biopsy Platform

More information and links to websites in the document attached

Preliminary Agenda

14:30 – 15:30 | Introduction to the BioRN Life Science Ecosystem & Regional Strengths + Q&A
15:30 – 16:00 | Networking Coffee Break
16:00 – 17:00 | Startup Presentations / Speed Networking Session
17:00 – 18:00 | Open Networking

Why Attend?

This event offers a unique opportunity to:

  • Discover innovative Korean biotech and medtech technologies.
  • Explore opportunities for joint R&D and scientific collaboration.
  • Identify partners for clinical studies and validation projects.
  • Discuss licensing, commercialization, and market expansion opportunities.
  • Expand your international network within the Korean and European life science ecosystems.

Join us in Heidelberg to connect with Korea’s emerging biotech innovators and explore future collaboration opportunities.

register now

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp